Research revealed that a single dose of the product can have an effect lasting approximately two weeks, with reduced KIT expression. Credit: Kmpzzz via Shutterstock.

Hoth Therapeutics has announced a master services agreement with Aronnax to advance the development of its HT-KIT cancer therapeutic.

HT-KIT is an antisense oligonucleotide that acts on the proto-oncogene cKIT.

Go deeper with GlobalData

Data Insights

The gold standard of business intelligence.

Find out more

It has shown potential in reducing KIT expression and effectively killing human mast cells in both cancerous and noncancerous cells.

The research on HT-KIT, conducted at NC State University, US, revealed that a single dose can have an effect lasting approximately two weeks, with reduced KIT expression observed for seven days.

The therapeutic also demonstrated the capability to diminish KIT expression using GIST cells and to initiate cell death within 48 to 72 hours, as well as lower the expression in AML cells over a 72-hour period.

See Also:

HT-KIT is being developed to treat mast cell-derived cancers and anaphylaxis and has received orphan drug designation from the US Food and Drug Administration (FDA).

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

Aronnax will manage the third-party provider, ITR Laboratories, which will conduct intravenous injection studies with varying doses.

These studies will determine the maximum dose and range-finding elements crucial for Hoth’s proposed clinical trials.

The timeframe for the study includes a 48-hour interval between each dose group.

This strategic partnership aims to provide Hoth with key metrics essential for the formulation of its clinical trial proposals.

Hoth Therapeutics CEO Robb Knie said: “We continue to make quick progress in moving HT-KIT from the lab to patients. This further analysis will help us with that process, finalising the protocols in our upcoming IND-enabling study.

“We are pleased to further engage Aronnax and ITR Laboratories on these key studies given their reputation for IND-enabling studies.”

In March 2021, Hoth and the University of Cincinnati Research Institute in the US entered into a research agreement to conduct antimicrobial characterisation studies for antibiotic HT-006.